A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes

Trial Profile

A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Tolimidone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors Melior Discovery
  • Most Recent Events

    • 13 Jun 2016 According to a a Melior Discovery media release, results from this study were presented at the 76th Sessions of the American Diabetes Association.
    • 13 Jun 2016 Results published in a Melior Discovery media release.
    • 13 Jun 2016 Primary endpoint has been met. (Change in PPG AUC0-3h in a MMTT between Days 1 and 29.), as reported in a Melior Discovery media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top